11C-methionine PET/CT

DIAGNOSTIC_TEST4 trials

Sponsors

Saitama Medical University, Tokushima University Hospital, Masaryk Memorial Cancer Institute, Imperial College London

Conditions

Brain tumorCushing's DiseaseGlioblastoma MultiformeHypercortisolismMalignant tumorPituitary ACTH Secreting AdenomaPituitary Adenoma

Phase 2

11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)

CompletedNCT05608395

Masaryk Memorial Cancer InstituteGlioblastoma Multiforme

Start: 2020-12-04End: 2024-06-20Updated: 2025-09-25

Unknown Phase

Evaluation study of diagnostic efficacy in malignant tumors using 11C-methionine PET/CT

Active, not recruitingJPRN-UMIN000002048

Saitama Medical UniversityMalignant tumor

Start: 2007-08-01Target: 1500Updated: 2026-06-29

Evaluation of usefulness in diagnosing brain tumors using 11C-methionine PET/CT

RecruitingJPRN-UMIN000003386

Tokushima University HospitalBrain tumor

Start: 2010-05-01Target: 100Updated: 2026-06-29

Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection

Not yet recruitingNCT06701838

Imperial College LondonCushing's Disease, Hypercortisolism, Pituitary ACTH Secreting Adenoma +1

Start: 2024-12-03End: 2026-07-05Target: 15Updated: 2024-12-03

Related Papers

P13.01.A 11C-METHIONIN PET FOR RADIOTHERAPY TREATMENT PLANNING IN PATIENTS WITH RAPID EARLY PROGRESSION AFTER GLIOBLASTOMA SURGERY: PROSPECTIVE PHASE II TRIAL

Neuro-Oncology2024-10-01

<sup>11</sup>C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET).

2024-06-153 citations